Abstract
Human parainfluenza virus-type 1 (hPIV-1) is the most common cause of pediatric laryngotracheobronchitis (croup) and results in close to 30,000 US hospitalizations each year. No effective vaccine is available. We examined murine PIV-1 (Sendai virus, SeV) as a live, xenotropic vaccine for the closely related human PIV-1 in a phase I, dose escalation study in healthy adults. Intranasal Sendai virus was uniformly well-tolerated and showed evidence of immunogenicity in three of nine vaccinees despite pre-existing, cross-reactive immunity presumably induced by previous exposure to human PIV-1. Results encourage future trials to evaluate the efficacy of Sendai virus in preventing human PIV-1 infection in infants and children.
Publication types
-
Clinical Trial
-
Clinical Trial, Phase I
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Administration, Intranasal
-
Adult
-
Animals
-
Antigen-Antibody Reactions
-
Chick Embryo
-
Cross Reactions
-
Dose-Response Relationship, Immunologic
-
Female
-
Humans
-
Male
-
Mice
-
Nasal Mucosa / immunology
-
Neutralization Tests
-
Parainfluenza Vaccines / adverse effects
-
Parainfluenza Vaccines / immunology
-
Parainfluenza Vaccines / therapeutic use*
-
Parainfluenza Virus 1, Human / immunology*
-
Respirovirus Infections / immunology*
-
Respirovirus Infections / prevention & control*
-
Vaccines, Attenuated / administration & dosage
-
Vaccines, Attenuated / adverse effects
-
Vaccines, Attenuated / immunology
Substances
-
Parainfluenza Vaccines
-
Vaccines, Attenuated